<h1 id="vasopressors-and-inotropes-in-shock">Vasopressors and Inotropes in Shock</h1>
<p>The treatment of shock should focus on correcting the underlying pathophysiology. With persistent hemodynamic instability, a vasopressor and/or inotrope should be selected. Reviewing receptor physiology can help you select the best-fit agent for the patient&#39;s clinical condition.</p>
<h2 id="physiologic-categories-of-shock">Physiologic Categories of Shock</h2>
<ul>
<li><strong>Cardiogenic:</strong><ul>
<li><em>Intrinsic disease</em>: myopathy, AMI, valvular dysfunction, arrhythmia</li>
<li><em>Extrinsic disease</em>: obstructive disorders (PE, pericardial tamponade, tension PTX)</li>
</ul>
</li>
<li><strong>Hypovolemic:</strong> bleeding, diarrhea, burns, third-spacing</li>
<li><strong>Distributive:</strong> sepsis, anaphylaxis, toxic shock syndrome, central neurologic injury</li>
</ul>
<h2 id="receptor-physiology">Receptor Physiology</h2>
<p><strong>Alpha-adrenergic receptors</strong></p>
<ul>
<li>Alpha-1 agonists cause vasoconstriction</li>
<li>Alpha-2 agonists causes vasodilatation esp. of coronary arteries</li>
</ul>
<p><strong>Beta-adrenergic receptors</strong></p>
<ul>
<li>Beta-1 agonists increases HR and cardiac contractility → increased CO</li>
<li>Beta-2 agonists dilate small coronary A’s, visceral organ A’s, skeletal muscle A’s and increase bronchodilation</li>
</ul>
<p><strong>Dopaminergic receptors</strong></p>
<ul>
<li>7 types of dopamine receptors.</li>
<li>D4 agonists increase cardiac contractility</li>
<li>D1 and D2 agonists increase renal diuresis and naturesis</li>
</ul>
<p><strong>Vasopressin receptors</strong></p>
<ul>
<li>V1 agonists cause vasoconstriction mostly in peripheral arterioles</li>
</ul>
<h2 id="medications">Medications</h2>
<p><strong><class span="drug">Epinephrine</span></strong></p>
<ul>
<li>Full range of alpha and beta agonist properties</li>
<li>Risk of dysrhythmias, AMI, abdominal organ ischemia</li>
<li>Dose 2-10 mcg/min mostly increases beta-1 effects</li>
<li>Dose &gt;10 mcg/min mostly increases alpha effects</li>
</ul>
<p><strong><class span="drug">Phenylephrine</span></strong></p>
<ul>
<li>Pure alpha agonist activity and minimally affects cardiac function directly</li>
</ul>
<p><strong><class span="drug">Norepinephrine</span></strong></p>
<ul>
<li>Alpha and beta agonist activity</li>
<li>Dose &lt; 2 mcg/min mostly beta-agonist effects</li>
<li>Dose &gt; 3 mcg/min adds alpha agonist effects</li>
<li>First line agent to improve BP for septic shock</li>
</ul>
<p><strong><class span="drug">Dopamine</span></strong></p>
<ul>
<li>Dose 0.5-2 mcg/kg/min stimulates D1 receptors</li>
<li>Dose 2-5 mcg/kg/min stimulates norepinephrine release</li>
<li>Dose 5-10 mcg/kg/min stimulates beta-1 activity</li>
<li>Dose &gt;10 mcg/kg/min stimulates both beta-1 and alpha activity</li>
<li><em>Surviving Sepsis Campaign</em> recommends <strong>dopamine</strong> or <strong>norepi</strong> as 1st-line agents</li>
</ul>
<p><strong><class span="drug">Dobutamine</span></strong></p>
<ul>
<li>Mainly beta-1 agonist --&gt; increased SV and CO with minimal affect on SVR</li>
<li>Less myocardial oxygen consumption</li>
</ul>
<h2 id="vasopressors-and-inotropes-in-shock-table-">Vasopressors and inotropes in shock (table)</h2>
<p><img src="https://d2p53dh3qxfm0x.cloudfront.net/uploads/img/1jx/5/m/b05f6e95-0a29-531e-af1f-c4ab1bd445fc/640.png" alt="">
From <a href="http://www.ncbi.nlm.nih.gov/pubmed/18655944">Ellender TJ, Skinner JC. Emerg Med Clin North Am. 2008</a></p>
<h2 id="references">References</h2>
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/pubmed/18655944">Ellender TJ, Skinner JC. Emerg Med Clin North Am. 2008 Aug;26(3):759-86.</a></li>
</ul>
